BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36362433)

  • 1. EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms.
    Venugopal A; Michalczyk A; Khasraw M; Ackland ML
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.
    Venugopal A; Gillick-Walker J; Michalczyk A; Khasraw M; Ackland ML
    BMC Gastroenterol; 2021 Apr; 21(1):194. PubMed ID: 33906633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer.
    Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y
    Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms.
    Khan MS; Luong TV; Watkins J; Toumpanakis C; Caplin ME; Meyer T
    Br J Cancer; 2013 May; 108(9):1838-45. PubMed ID: 23579216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.
    Modlin IM; Drozdov I; Kidd M
    PLoS One; 2013; 8(5):e63364. PubMed ID: 23691035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
    Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
    Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
    González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
    Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
    Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
    Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single institutional experience on primary neuroendocrine neoplasms of the kidney: a rare distinct entity.
    Amin M; Trikalinos N; Chatterjee D
    Hum Pathol; 2021 Aug; 114():36-43. PubMed ID: 33891968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition.
    McCorry AM; Loughrey MB; Longley DB; Lawler M; Dunne PD
    J Pathol; 2018 Dec; 246(4):422-426. PubMed ID: 30105762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
    Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
    World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
    Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
    Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
    BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers.
    Luo Z; Li Y; Zuo M; Liu C; Tian W; Yan D; Wang H; Li D
    Mol Carcinog; 2017 May; 56(5):1438-1448. PubMed ID: 27996162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.